Lung Cancer Update: Advances in Screening, Diagnostics and Therapeutics

The Johns Hopkins University and UNC Chapel Hill Divisions of Pulmonary and Critical Care Medicine, as well as the UNC Lineberger Comprehensive Cancer Center, are pleased to present an update in lung cancer screening, diagnostics and therapeutics.

When Jun 20, 2014 from 07:30 AM to 04:30 PM (US/Eastern / UTC-400)
Where The William and Ida Friday Center for Continuing Education
University of North Carolina at Chapel Hill
100 Friday Center Dr, Chapel Hill, NC 27517
Contact Name
Contact Phone (410) 502-9634
  • This activity is intended for family practitioners, internists, oncologists, pulmonologists, radiation oncologists and thoracic surgeons.
Add event to calendar iCal

Download or print the event brochure

Through this accredited CME activity, we will cover new recommendations and cutting edge research in the area of lung cancer.

Lung cancer is the leading cause of cancer death in the United States, with an estimated 220,000 new diagnoses of lung cancer in 2013 resulting in an estimated 150,000 deaths, making lung cancer more deadly than breast, prostate and colon cancer combined. Although the number of new cases of lung cancer is declining, the death rates continues to be staggering.

Recent advances in lung cancer research have provided improved understanding and stratification of different types of non-small-cell lung cancer. This has led to a further research which has and continues to identify targetable molecular and genetic mutations. As our knowledge improves, the previous practice to treat all non-small-cell lung cancer with cytotoxic chemotherapeutic agents has undergone immense change. We are now entering an era of personalized therapy in which lung cancer is characterized by specific potentially targetable genetic alterations. Added to advances in our understanding of lung cancer genetics, the USPTF has recently recommended lung cancer screening in a select group of high risk individuals.

Bridging the gap between what physicians understand about cancer detection, biology, its application to clinical oncology and advances in radiotherapy and surgery make implementation of the cutting edge of treatment of even greater importance. Moreover, facilitating the interface between different disciplines of physicians and scientists has and will continue to increase our knowledge as a medical community. We will address these issues and their potential effect on future practice patterns in an effort to continue to improve lung cancer care.